Knight Therapeutics Inc., of Montreal, inked a strategic partnership with Neuraxon Inc., of Mississauga, Ontario, to commercialize products in development by Neuraxon in Canada, Israel, South Africa and Russia. Knight will pay approximately $1.75 million in cash and provide additional funding to develop the products.